Dr. Jonasch on recent pivotal advances in renal cell carcinoma

Eric Jonasch, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses significant developments in renal cell carcinoma (RCC) over the last several years. He specifically focuses on the incorporation of immune checkpoint inhibitors into the frontline treatment of RCC and the emergence of HIF-2α inhibitors, such as belzutifan (Welireg).